{"id":1398,"date":"2016-11-01T17:29:57","date_gmt":"2016-11-01T11:59:57","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1398"},"modified":"2021-07-24T12:56:34","modified_gmt":"2021-07-24T07:26:34","slug":"notizia-12","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-12","title":{"rendered":"Sun Pharma Announces Launch; OptiNose files; Opiant obtains rights; Swissmedic approves"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a03051e4106a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a03051e4106a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-12\/#Sun_Pharma_Announces_US_Launch_of_Authorized_Generics_for_Benicar_Benicar_HCT_Azor_and_Tribenzor\" >Sun Pharma Announces US Launch of Authorized Generics for Benicar, Benicar HCT, Azor and Tribenzor<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-12\/#OptiNose_is_preparing_to_file_its_new_chronic_rhinosinusitis_remedy_for_FDA_approval_by_years_end\" >OptiNose is preparing to file\u00a0its new chronic rhinosinusitis remedy for FDA approval by year&#8217;s end.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-12\/#Opiant_Pharmaceuticals_obtains_development_and_commercialization_rights_for_heroin_vaccine\" >Opiant Pharmaceuticals obtains development and commercialization rights for heroin vaccine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-12\/#Swissmedic_approves_Sobis_Alprolix_to_treat_haemophilia_B\" >Swissmedic approves Sobi\u2019s Alprolix to treat haemophilia B<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-12\/#Humiras_ppor_performance_triggers_Q3_sales_miss_for_AbbVie_but_SG_A_beat_keeps_EPS_in_line\" >Humira\u2019s ppor performance triggers Q3 sales miss for AbbVie, but SG&amp;A beat keeps EPS in line<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Sun_Pharma_Announces_US_Launch_of_Authorized_Generics_for_Benicar_Benicar_HCT_Azor_and_Tribenzor\"><\/span>Sun Pharma Announces US Launch of Authorized Generics for Benicar, Benicar HCT, Azor and Tribenzor<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all strengths of Olmesartan Medoxomil tablets, Olmesartan Medoxomil-Hydrochlorothiazide tablets, Amlodipine Besylate-Olmesartan Medoxomil tablets, and Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets. The launch is pursuant to a distribution and supply agreement between Sun Pharma\u2019s wholly owned subsidiary and\u00a0Daiichi Sankyo Inc., which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US\u00a0for a pre-determined period.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"OptiNose_is_preparing_to_file_its_new_chronic_rhinosinusitis_remedy_for_FDA_approval_by_years_end\"><\/span>OptiNose is preparing to file\u00a0its new chronic rhinosinusitis remedy for FDA approval by year&#8217;s end.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">OptiNose is preparing to file\u00a0its new chronic rhinosinusitis remedy for FDA approval by year&#8217;s end, with an eye to a potential launch in 2017. OptiNose-delivered fluticasone spray\u00a0is a potential cure for patients suffering from chronic nasal and sinus problems. The drug is a widely used nasal steroid&#8211;but the delivery device is novel. Unlike traditional nasal inhalers, OptiNose\u2019s device uses two pathways, one into the mouth and the other into the patient\u2019s nostrils. Patients insert the device and exhale to dispense a dose.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Opiant_Pharmaceuticals_obtains_development_and_commercialization_rights_for_heroin_vaccine\"><\/span>Opiant Pharmaceuticals obtains development and commercialization rights for heroin vaccine<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Opiant Pharmaceuticals\u00a0has secured exclusive development and commercialization rights to the heroin vaccine invented by scientists at the\u00a0Walter Reed Army Institute of Research\u00a0(WRAIR) and the\u00a0National Institute on Drug Abuse\u00a0(NIDA), a division of the\u00a0National Institutes of Health\u00a0(NIH).\u00a0Researchers developed a vaccine candidate that induces antibodies that then bind to heroin in the bloodstream, thereby preventing the drug from crossing the blood-brain barrier and blocking the euphoria and addictive effects. As heroin is too small a molecule to induce antibodies on its own, scientists worked with organic chemists to join the heroin analog to a carrier protein in order to boost its immune-inducing effect.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Swissmedic_approves_Sobis_Alprolix_to_treat_haemophilia_B\"><\/span>Swissmedic approves Sobi\u2019s Alprolix to treat haemophilia B<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">The Swiss Agency for Therapeutic Products, Swissmedic, has approved Sobi\u2019s Alprolix (eftrenonacog alfa) for the treatment of haemophilia B. Alprolix has been developed for haemophilia B by fusing factor IX to the F<sub>c<\/sub> portion of immunoglobulin G subclass 1, or IgG1. It is currently approved for the treatment of haemophilia B in the EU, Iceland, Liechtenstein and Norway, as well as the US, Canada, Japan, Australia, New Zealand and other countries.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Humiras_ppor_performance_triggers_Q3_sales_miss_for_AbbVie_but_SG_A_beat_keeps_EPS_in_line\"><\/span>Humira\u2019s ppor performance triggers Q3 sales miss for AbbVie, but SG&amp;A beat keeps EPS in line<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">For the third quarter, AbbVie bested analyst expectations in several areas. There was just one issue: The Company missed on revenue, and specifically on revenue for closely watched behemoth Humira. AbbVie\u2019s top-line haul checked in at $6.39 billion, falling $173 million short of consensus estimates. And the company\u2019s top seller was a big reason for the gap, with U.S. sales of $2.65 million underperforming expectations by $107 million&#8211;and ex-U.S. sales missing slightly, too. In the drug\u2019s three major market segments, Humira is standing its ground despite increasing competition from next-gen meds and biosimilars of its anti-TNF rivals.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharma Announces US Launch of Authorized Generics for Benicar, Benicar HCT, Azor and Tribenzor Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all strengths of Olmesartan Medoxomil tablets, Olmesartan Medoxomil-Hydrochlorothiazide tablets, Amlodipine Besylate-Olmesartan Medoxomil tablets, and Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets. The launch [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1247,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17385,17386,16963,802,17384],"industry":[17225],"therapeutic_areas":[17242],"class_list":["post-1398","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-haemophilia-b","tag-opiant-pharmaceuticals","tag-optinose","tag-sun-pharma","tag-swissmedic","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sun Pharma Announces;OptiNose files;Opiant obtains right<\/title>\n<meta name=\"description\" content=\"Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-12\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun Pharma Announces;OptiNose files;Opiant obtains right\" \/>\n<meta property=\"og:description\" content=\"Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-12\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-01T11:59:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"681\" \/>\n\t<meta property=\"og:image:height\" content=\"243\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sun Pharma Announces;OptiNose files;Opiant obtains right","description":"Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-12","og_locale":"en_US","og_type":"article","og_title":"Sun Pharma Announces;OptiNose files;Opiant obtains right","og_description":"Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-12","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-11-01T11:59:57+00:00","article_modified_time":"2021-07-24T07:26:34+00:00","og_image":[{"width":681,"height":243,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-12","url":"https:\/\/www.delveinsight.com\/blog\/notizia-12","name":"Sun Pharma Announces;OptiNose files;Opiant obtains right","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-12#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-12#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg","datePublished":"2016-11-01T11:59:57+00:00","dateModified":"2021-07-24T07:26:34+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-12"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-12#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg","width":681,"height":243},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02-300x107.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">haemophilia B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Opiant Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">OptiNose<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sun Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Swissmedic<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">haemophilia B<\/span>","<span class=\"advgb-post-tax-term\">Opiant Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">OptiNose<\/span>","<span class=\"advgb-post-tax-term\">Sun Pharma<\/span>","<span class=\"advgb-post-tax-term\">Swissmedic<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 1, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 1, 2016 5:29 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1398"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1398\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1247"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1398"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1398"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}